The Newest Treatment for FSGS: Immunotherapy

Focal Segmental Glomerulosclerosis (FSGS) is an autoimmune disease. Immune disorder or deficiency is attributed to the incidence of the disease. Therefore, the right way to treat FSGS is to correct the immune system and repair the impaired kidney structure.

For healthy people, when the external pathological substances as antigens invade into body, the immune system can activate the related antibodies to fight the antigens. After the antigens are eliminated, the immune complexes of antigens and antibodies will be brought out of body through systemic circulation.

However, in some cases, the immune complexes can not be removed and they will enter into kidneys and deposit in the epithelial cells of the glomeruli. These immune complexes attract inflammatory factors gradually thus leading to inflammation of glomeruli. As a result, the epithelial cells are impaired and lost their barrier function. In clinic, the persons are diagnosed with FSGS and will present hematuria, proteinuria etc and other symptoms of FSGS.

The conventional therapies only focus on reliving the symptoms of FSGS and suppressing the inflammation reaction. However, it can not remove the immune complexes. Therefore, the disease often relapses frequently and finally develops into End Stage Renal Failure.

Immunotherapy treats FSGS from its underlying causes. It can remove the immune complexes in kidneys, block the inflammation reaction as well as restore the impaired renal epithelial cells. It can inhibit the renal fibrosis fundamentally and stop the renal function decline from its root cause.


Immunotherapy is aims at correcting the body's own immune system and recover the abnormal protection function of the body. It does not cause side effects to patients at all.